UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000044503
Receipt No. R000050842
Scientific Title Study on the absorption and urinary excretion of minerals by intake of mulberry leaf green juice and baby oligo.
Date of disclosure of the study information 2021/06/26
Last modified on 2021/10/12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Study on the absorption and urinary excretion of minerals by intake of mulberry leaf green juice and baby oligo.
Acronym Study on the absorption and urinary excretion of minerals by intake of mulberry leaf green juice and baby oligo.
Scientific Title Study on the absorption and urinary excretion of minerals by intake of mulberry leaf green juice and baby oligo.
Scientific Title:Acronym Study on the absorption and urinary excretion of minerals by intake of mulberry leaf green juice and baby oligo.
Region
Japan

Condition
Condition Healthy Adults
Classification by specialty
Not applicable
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Evaluate the minerals absorption effect when mulberry leaf green juice and baby oligo with minerals are taken by adults aged more than 20 years old and less than 65 years old.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Urinary calcium, urinary magnesium, urinary iron and urinary zinc content.
Key secondary outcomes Urinary calcium/creatinine ratio, Urinary magnesium/creatinine ratio, Urinary iron/creatinine ratio, Urinary zinc/creatinine ratio, Urinary hydroxyproline content.

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 3
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg and zinc sulphate 44.0 mg.
Washout for 1week or more.
Intake of calcium carbonate 2139.6 mg, magnesium oxide 803.4 mg, sodium ferrous citrate 85.5 mg, zinc sulphate 43.5 mg and mulberry leaf green juice 8.0 g.
Washout for 1week or more.
Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg, zinc sulphate 44.0 mg and baby oligo 7.5

*Intake with breakfast.
*Eat prescribed diet for breakfast and lunch.
*Drink distilled water for something to drink.
Interventions/Control_2 Intake of calcium carbonate 2139.6 mg, magnesium oxide 803.4 mg, sodium ferrous citrate 85.5 mg, zinc sulphate 43.5 mg and mulberry leaf green juice 8.0 g.
Washout for 1week or more.
Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg, zinc sulphate 44.0 mg and baby oligo 7.5
Washout for 1week or more.
Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg and zinc sulphate 44.0 mg.

*Intake with breakfast.
*Eat prescribed diet for breakfast and lunch.
*Drink distilled water for something to drink.
Interventions/Control_3 Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg, zinc sulphate 44.0 mg and baby oligo 7.5
Washout for 1week or more.
Intake of calcium carbonate 2497.2 mg, magnesium oxide 829.0 mg, sodium ferrous citrate 94.2 mg and zinc sulphate 44.0 mg.
Washout for 1week or more.
Intake of calcium carbonate 2139.6 mg, magnesium oxide 803.4 mg, sodium ferrous citrate 85.5 mg, zinc sulphate 43.5 mg and mulberry leaf green juice 8.0 g.

*Intake with breakfast.
*Eat prescribed diet for breakfast and lunch.
*Drink distilled water for something to drink.
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
65 years-old >
Gender Male and Female
Key inclusion criteria 1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document
2.Healthy Japanese who are more than 20 years old and less than 65 years old.
Key exclusion criteria 1.Persons who have chronic illness, receiving medication, have a serious disease history
2.Persons who are allergic to the test food
3.Persons who usually take a large amount of test food
4.Persons who usually take medicine, specified health food, healthy food that may affect mineral absorption.
5.Persons who have participated in other tests within the first month before the start of the test, or those who intend to participate in another exam after consenting to this exam
6.Persons who were judged as inappropriate for study participants by the principal investigator
7.Persons who are pregnant, planning or hoping to be pregnant during the study period, breastfeeding
Target sample size 10

Research contact person
Name of lead principal investigator
1st name Nozomi
Middle name
Last name Ando
Organization Natural Science Co.,Ltd.
Division name Research and Development Department
Zip code 136-0073
Address 3-4-27 Kitasuna, Koto-ku, Tokyo 136-0073, JAPAN
TEL 03-5665-2311
Email ando@natural-s.jp

Public contact
Name of contact person
1st name Kosei
Middle name
Last name Nishikawa
Organization Healthcare Systems Co., Ltd.
Division name Research and Development Department
Zip code 105-0004
Address Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN
TEL 03-6809-2722
Homepage URL
Email nishikawa@hc-sys.jp

Sponsor
Institute Healthcare Systems Co., Ltd.
Institute
Department

Funding Source
Organization Healthcare Systems Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization The Ethics Committee of Healthcare Systems Co., Ltd.
Address Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN
Tel 03-6809-2722
Email soumu@hc-sys.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 06 Month 26 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 10
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2021 Year 06 Month 01 Day
Date of IRB
2021 Year 06 Month 01 Day
Anticipated trial start date
2021 Year 06 Month 30 Day
Last follow-up date
2021 Year 09 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2021 Year 06 Month 11 Day
Last modified on
2021 Year 10 Month 12 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050842

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.